论文部分内容阅读
目的探讨胸腺肽治疗初治涂阳空洞性肺结核患者的临床价值。方法将100例初治涂阳空洞性肺结核患者随机分为对照组和治疗组。对照组50例按常规抗结核化疗方案(INH+RFP+PZA+EMB)治疗,治疗组在对照组治疗基础上加用胸腺肽100 mg静脉滴注,1次/d,2个月为1个疗程,两组总疗程均为6个月。结果治疗组痰菌阴转率为98%,明显优于对照组的86%(P<0.05);治疗组空洞缩小率为92.0%,明显优于对照组的76.0%(P<0.05);治疗组病灶吸收率为96.0%,明显高于对照组的82.0%(P<0.05)。结论胸腺肽用于治疗初治涂阳空洞性肺结核患者能明显促进患者痰菌阴转,促使空洞闭合,病灶吸收,值得临床应用。
Objective To investigate the clinical value of thymosin in the treatment of initially-smear-positive pulmonary tuberculosis. Methods 100 cases of newly diagnosed smear-positive pulmonary tuberculosis patients were randomly divided into control group and treatment group. Control group of 50 patients treated by conventional anti-TB chemotherapy (INH + RFP + PZA + EMB) treatment group in the control group based on the treatment with thymosin 100 mg intravenous infusion, 1 / d, 2 months for a course of treatment The total course of treatment was 6 months in both groups. Results The sputum negative conversion rate in the treatment group was 98%, which was significantly better than that in the control group (P <0.05). The shrinkage rate of the cavity in the treatment group was 92.0%, which was significantly better than that in the control group (76.0%, P <0.05) The absorptivity of the group of lesions was 96.0%, which was significantly higher than that of the control group (82.0%, P <0.05). Conclusion Thymosin for the treatment of patients with initially smear-positive pulmonary tuberculosis can significantly promote patients with sputum negative conversion, promote empty closure, the lesion absorption, it is worth clinical application.